Development and Evaluation of Bilayer Sustained-Release Tablets of Ruxolitinib Using Discriminative Pharmacokinetic Analysis and IVIVC

Development and Evaluation of Bilayer Sustained-Release Tablets of Ruxolitinib Using Discriminative Pharmacokinetic Analysis and IVIVC

<b>Objectives</b>: This study explores the development and evaluation of a bilayer sustained-release (SR) tablet formulation of ruxolitinib. As a BCS Class 1 drug, ruxolitinib requires twice-daily dosing due to its short half-life. We designed a bilayer tablet that integrates immediate-r...

Full description

Saved in:
Bibliographic Details
Main Authors: Namhyuck Kim, Kyoungho Kim, Seungwei Jeong, Jiyeong Kim, Helen Cho, Young-Joo Lee, Sangyeob Park
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Pharmaceutics
Subjects:
bilayer tablet
sustained release formulation
ruxolitinib
IVIVC
dissolution
Online Access:https://www.mdpi.com/1999-4923/17/4/432
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items